Against the mutant L100I and K103N RT HIV-1 strains in MT-4 cells, some compounds showed antiviral potency superior to that of NVP and EFV. against a panel of human respiratory viruses including influenza A virus (FLU-A, A/PR/8/34H1N1), Respiratory Syncytial Virus (RSV), Human rhinovirus (HRV) 14, coxsackie Gw274150 virus B3 (CVB3), adenovirus type 7 (AdV-7) and HCV , , . Delavirdine 11 (Rescriptor, Fig.?2) is a first generation non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It was approved by FDA in 1997 for the treatment of human immunodeficiency virus type 1 (HIV-1). It is used as part of highly active antiretroviral therapy (HAART) . Since then, better NNRTI such as efavirenz, and second generation NNRTIs such as etravirine and rilpivirine have been approved (http://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-medicines). Delavirdine inhibits the CYP3A4-mediated metabolism of HIV protease inhibitors and thereby increases systemic exposure to protease inhibitors. The ability of delavirdine to enhance the pharmacokinetic profiles of protease inhibitors may permit the use of simplified administration regimens . Atevirdine 12 (U-87201E, Fig.?2) is a new non-nucleoside (heteroarylpiperazine) reverse transcriptase inhibitor that has been studied for the treatment of HIV . Atevirdine mesylate has been shown to have significant anti-HIV RT activity ADME profiles, and compound 16 provided the most optimal balance between antiviral potency and a consistent cross-species PK profile, it was selected for development followed by a clinical study in HCV-infected patients . BMS-791325 17 (Fig.?2), a cyclopropyl-fused indolobenzazepine HCV NS5B RNA-dependent polymerase inhibitor, it inhibited cellar replication of HCV subgenomic replicons representing genotypes 1a and 1b at EC50 of 3?nM and 6?nM, respectively, it also exhibited notably enhanced pharmacokinetic profiles with improved solubility and membrane permeability, it was found to perform distinguishing antiviral, safety, and pharmacokinetic properties that resulted in its selection for clinical evaluation, Phase III studies are currently ongoing . MK-8742 18 (Fig.?2), a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clinical trials as part of an all-oral, interferon-free Cd248 regimen for the treatment of HCV infection . As NS5A protein plays a critical role in the replication of HCV and its inhibitors have shown impressive potency profiles in HCV replicon assays, making NS5A inhibitors attractive components for inclusion in all oral combination regimens. MK-8742, is a second generation NS5A inhibitor. In combination with MK-5172, an NS3/4A protease inhibitor, this candidate drug exhibited improvements in the genetic barrier while maintaining potency, yielding amazing results in terms of efficacy (90C100%), tolerability and safety, Phase II clinical trials are underway. In an interim analysis of treatment-na?ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin (RBV), a sustained viral response (SVR) was observed in 98 percent (42/43) of patients administered MK-5172/MK-8742 alone and 94 percent (75/80) in those administered MK-5172/MK-8742 plus RBV. This kind of interferon-free therapies is expected to lead the HCV treatment if the high cost is overcome , . Enfuvirtide (T-20; brand name: Fuzeon) 19 (Fig.?2), the peptide anti-HIV drug targeting gp41N-terminal heptad repeat (NHR), was approved by the U.S. FDA in 2003 as the first HIV fusion/entry inhibitor for treatment of HIV/AIDS Gw274150 patients who fail to respond to the current antiretroviral drugs. However, because T20 lacks the pocket-binding domain, it exhibits low anti-HIV-1 activity and short half-life . TMC647055 25 (Fig.?3 ), a nonzwitterionic 17-membered macrocyclic indole, has yielded potent and selective finger-loop inhibitors of the hepatitis C virus (HCV) NS5B polymerase . Lead optimization from 20 to 25 in conjunction with evaluation in rats identified this compound showing nanomolar potency (EC50?=?77?nM) in HCV replicon cells, limited toxicity and offCtarget activities, and encouraging preclinical pharmacokinetic profiles characterized by high liver distribution, and it is currently being evaluated in phase II clinical Gw274150 trials in Gw274150 combination with.
Against the mutant L100I and K103N RT HIV-1 strains in MT-4 cells, some compounds showed antiviral potency superior to that of NVP and EFV